Sansure

Mycobacterium Tuberculosis Nucleic Acid and Rifampicin Resistance Fluorescence Diagnostic Kit (PCR-Fluorescence Probing)

TB and RFP

- Testing as Treatment
- Easy to operate
- Short time

www.sansureglobal.com

WHO The End TB Strategy

Ending TB is not just a public health problem, but a development challenge and opportunity. WHO's post-2015 End TB Strategy, adopted by the World Health Assembly in 2014, aims to end the global TB epidemic as part of the newly adopted Sustainable Development Goals.

It serves as a blueprint for countries to reduce TB incidence by 80%, TB deaths by 90%, and to eliminate catastrophic costs for TB-affected households by 2030.

PARAMETERS

Product features	Parameter
Specimen Types	Sputum
Technical Platform	One-tube fast release technology
PCR Instruments	iPonatic III (S-Q36A)
Internal Control	RNase P
Limit of detection	Mycobacterium tuberculosis 1000 Bacteria/mL; Rifampicin resistance 10000 Bacteria/mL

ORDER INFORMATION

Product No.	Product Name	Spec.
S3363E-12-P	Mycobacterium Tuberculosis Nucleic Acid and Rifampicin Resistance Fluorescence Diagnostic Kit (PCR-Fluorescence Probing)	Pre-packaged 12T/kit
S1012E	Sample Release Reagent	24T/kit, 48T/kit
S50016E	Nucleic Acid Extraction-Purification Kit	24T, 48T, 96T/Kit
Y1001E	Sample Diluent	24T, 96T/Kit

CLINICAL VALUES

To improve the efficiency of drug resistance detection in patients
Patients with a clear diagnosis should be given timely and correct treatment
Helps doctors to take full supervised treatment

Sansure
SANSURE BIOTECH INC.
ADDR : No 680, Lusong Roaa, Yuelu District, Changsha, Hunan Province, 410205, P.R. China
TEL : + 86-731-88883176-6116
FAX : + 86-731-89736985
MAIL : info@sansure.com.cn/support@sansure.com.cn
WEB : www.sansureglobal.com

SCAN ME

20221205